| Odelia Healthcare | |
| 1509 University Boulevard Ne, Albuquerque, New Mexico 87102 | |
| (505) 243-2257 | |
| Name | Odelia Healthcare |
|---|---|
| Location | 1509 University Boulevard Ne, Albuquerque, New Mexico |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 119 |
| Occupancy Rate | 83.7% |
| Medicare ID (CCN) | 325060 |
| Legal Business Name | Camino Healthcare Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1134167679 |
| Organization Name | PALOMA BLANCA HEALTH CARE ASSOCIATES, LLC |
| Doing Business As | PALOMA BLANCA HEALTH AND REHABILITATION |
| Address | 1509 University Blvd Ne, Albuquerque, NM 87102 |
| Phone Number | 505-243-2257 |
News Archive
Each time a cell divides, the protective caps at the ends of chromosomes shorten - and when these caps are gone, so are we. Now, by using an unconventional strategy to shorten telomeres in mice, researchers at Rockefeller University have not only created the first faithful mouse model for studying a rare yet fatal premature aging syndrome, but they have revealed the molecular defect behind the disease.
A recently approved angina drug may also represent a powerful new treatment for a rare hereditary syndrome that places teens at risk for sudden cardiac death, according to research presented at the 57th Annual Scientific Sessions of the American College of Cardiology (ACC) in Chicago.
The proportion of women age 65 and over on Medicare who said that they had been screened for osteoporosis increased from 34 percent in 2001 to 64 percent in 2006, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
BioInvent International announced today that the first patient has been treated in a phase II study of the drug candidate BI-505, developed for the treatment of multiple myeloma.
Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1 clinical study of VT-1161, an oral, potent and selective antifungal agent. VT-1161 is a novel small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile Technology.
› Verified 3 days ago
| NPI Number | 1316418726 |
| Organization Name | ALBUQUERQUE CARE HOLDINGS LLC |
| Address | 1509 University Blvd Ne, Albuquerque, NM 87102 |
| Phone Number | 505-243-2257 |
News Archive
Each time a cell divides, the protective caps at the ends of chromosomes shorten - and when these caps are gone, so are we. Now, by using an unconventional strategy to shorten telomeres in mice, researchers at Rockefeller University have not only created the first faithful mouse model for studying a rare yet fatal premature aging syndrome, but they have revealed the molecular defect behind the disease.
A recently approved angina drug may also represent a powerful new treatment for a rare hereditary syndrome that places teens at risk for sudden cardiac death, according to research presented at the 57th Annual Scientific Sessions of the American College of Cardiology (ACC) in Chicago.
The proportion of women age 65 and over on Medicare who said that they had been screened for osteoporosis increased from 34 percent in 2001 to 64 percent in 2006, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
BioInvent International announced today that the first patient has been treated in a phase II study of the drug candidate BI-505, developed for the treatment of multiple myeloma.
Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1 clinical study of VT-1161, an oral, potent and selective antifungal agent. VT-1161 is a novel small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile Technology.
› Verified 3 days ago
| NPI Number | 1407361009 |
| Organization Name | ABQ POST ACUTE, LLC |
| Doing Business As | ALBUQUERQUE POST ACUTE |
| Address | 1509 University Blvd Ne, Albuquerque, NM 87102 |
| Phone Number | 408-348-7566 |
News Archive
Each time a cell divides, the protective caps at the ends of chromosomes shorten - and when these caps are gone, so are we. Now, by using an unconventional strategy to shorten telomeres in mice, researchers at Rockefeller University have not only created the first faithful mouse model for studying a rare yet fatal premature aging syndrome, but they have revealed the molecular defect behind the disease.
A recently approved angina drug may also represent a powerful new treatment for a rare hereditary syndrome that places teens at risk for sudden cardiac death, according to research presented at the 57th Annual Scientific Sessions of the American College of Cardiology (ACC) in Chicago.
The proportion of women age 65 and over on Medicare who said that they had been screened for osteoporosis increased from 34 percent in 2001 to 64 percent in 2006, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
BioInvent International announced today that the first patient has been treated in a phase II study of the drug candidate BI-505, developed for the treatment of multiple myeloma.
Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1 clinical study of VT-1161, an oral, potent and selective antifungal agent. VT-1161 is a novel small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile Technology.
› Verified 3 days ago
| NPI Number | 1619233947 |
| Address | 1509 University Blvd Ne, Albuquerque, NM 87102 |
| Phone Number | 505-243-2257 |
News Archive
Each time a cell divides, the protective caps at the ends of chromosomes shorten - and when these caps are gone, so are we. Now, by using an unconventional strategy to shorten telomeres in mice, researchers at Rockefeller University have not only created the first faithful mouse model for studying a rare yet fatal premature aging syndrome, but they have revealed the molecular defect behind the disease.
A recently approved angina drug may also represent a powerful new treatment for a rare hereditary syndrome that places teens at risk for sudden cardiac death, according to research presented at the 57th Annual Scientific Sessions of the American College of Cardiology (ACC) in Chicago.
The proportion of women age 65 and over on Medicare who said that they had been screened for osteoporosis increased from 34 percent in 2001 to 64 percent in 2006, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
BioInvent International announced today that the first patient has been treated in a phase II study of the drug candidate BI-505, developed for the treatment of multiple myeloma.
Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1 clinical study of VT-1161, an oral, potent and selective antifungal agent. VT-1161 is a novel small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile Technology.
› Verified 3 days ago
| NPI Number | 1699178418 |
| Organization Name | GENESIS REHAB SERVICES |
| Address | 1509 University Blvd Ne, Albuquerque, NM 87102 |
| Phone Number | 505-242-4656 |
News Archive
Each time a cell divides, the protective caps at the ends of chromosomes shorten - and when these caps are gone, so are we. Now, by using an unconventional strategy to shorten telomeres in mice, researchers at Rockefeller University have not only created the first faithful mouse model for studying a rare yet fatal premature aging syndrome, but they have revealed the molecular defect behind the disease.
A recently approved angina drug may also represent a powerful new treatment for a rare hereditary syndrome that places teens at risk for sudden cardiac death, according to research presented at the 57th Annual Scientific Sessions of the American College of Cardiology (ACC) in Chicago.
The proportion of women age 65 and over on Medicare who said that they had been screened for osteoporosis increased from 34 percent in 2001 to 64 percent in 2006, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
BioInvent International announced today that the first patient has been treated in a phase II study of the drug candidate BI-505, developed for the treatment of multiple myeloma.
Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1 clinical study of VT-1161, an oral, potent and selective antifungal agent. VT-1161 is a novel small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile Technology.
› Verified 3 days ago
| NPI Number | 1811552359 |
| Organization Name | ODELIA HEALTHCARE LLC |
| Doing Business As | CAMINO HEALTHCARE |
| Address | 1509 University Blvd Ne, Albuquerque, NM 87102 |
| Phone Number | 505-243-2257 |
News Archive
Each time a cell divides, the protective caps at the ends of chromosomes shorten - and when these caps are gone, so are we. Now, by using an unconventional strategy to shorten telomeres in mice, researchers at Rockefeller University have not only created the first faithful mouse model for studying a rare yet fatal premature aging syndrome, but they have revealed the molecular defect behind the disease.
A recently approved angina drug may also represent a powerful new treatment for a rare hereditary syndrome that places teens at risk for sudden cardiac death, according to research presented at the 57th Annual Scientific Sessions of the American College of Cardiology (ACC) in Chicago.
The proportion of women age 65 and over on Medicare who said that they had been screened for osteoporosis increased from 34 percent in 2001 to 64 percent in 2006, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
BioInvent International announced today that the first patient has been treated in a phase II study of the drug candidate BI-505, developed for the treatment of multiple myeloma.
Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1 clinical study of VT-1161, an oral, potent and selective antifungal agent. VT-1161 is a novel small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile Technology.
› Verified 3 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Each time a cell divides, the protective caps at the ends of chromosomes shorten - and when these caps are gone, so are we. Now, by using an unconventional strategy to shorten telomeres in mice, researchers at Rockefeller University have not only created the first faithful mouse model for studying a rare yet fatal premature aging syndrome, but they have revealed the molecular defect behind the disease.
A recently approved angina drug may also represent a powerful new treatment for a rare hereditary syndrome that places teens at risk for sudden cardiac death, according to research presented at the 57th Annual Scientific Sessions of the American College of Cardiology (ACC) in Chicago.
The proportion of women age 65 and over on Medicare who said that they had been screened for osteoporosis increased from 34 percent in 2001 to 64 percent in 2006, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
BioInvent International announced today that the first patient has been treated in a phase II study of the drug candidate BI-505, developed for the treatment of multiple myeloma.
Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1 clinical study of VT-1161, an oral, potent and selective antifungal agent. VT-1161 is a novel small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile Technology.
› Verified 3 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $3250 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 20.4 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 7.66 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 57.35 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.51 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0.39 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.86 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 96.19 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 13.98 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 71.33 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0.67 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 28.03 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 13.91 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 6.78 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 78.66 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 68.73 | 82.93 |
News Archive
Each time a cell divides, the protective caps at the ends of chromosomes shorten - and when these caps are gone, so are we. Now, by using an unconventional strategy to shorten telomeres in mice, researchers at Rockefeller University have not only created the first faithful mouse model for studying a rare yet fatal premature aging syndrome, but they have revealed the molecular defect behind the disease.
A recently approved angina drug may also represent a powerful new treatment for a rare hereditary syndrome that places teens at risk for sudden cardiac death, according to research presented at the 57th Annual Scientific Sessions of the American College of Cardiology (ACC) in Chicago.
The proportion of women age 65 and over on Medicare who said that they had been screened for osteoporosis increased from 34 percent in 2001 to 64 percent in 2006, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
BioInvent International announced today that the first patient has been treated in a phase II study of the drug candidate BI-505, developed for the treatment of multiple myeloma.
Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1 clinical study of VT-1161, an oral, potent and selective antifungal agent. VT-1161 is a novel small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile Technology.
› Verified 3 days ago
Sandia Ridge Center Location: 2216 Lester Drive Ne, Albuquerque, New Mexico 87112 Phone: (505) 296-4808 | |
The Rehabilitation Center Of Albuquerque Location: 5900 Forest Hills Drive Ne, Albuquerque, New Mexico 87109 Phone: (505) 822-6000 | |
Las Palomas Center Location: 8100 Palomas Avenue Ne, Albuquerque, New Mexico 87109 Phone: (505) 821-4200 | |
Uptown Rehabilitation Center Location: 7900 Constitution Avenue Ne, Albuquerque, New Mexico 87110 Phone: (505) 296-5565 |